Basic Information


GTO ID GTC2887
Trial ID NCT05188469
Disease COVID-19
TherapymRNA vaccine
Treatment EG-COVID-003|EG-COVID-001|EG-COVID|EG-COVARo
PhasePhase1|Phase2
Recruitment statusRecruiting
TitleA Phase I/IIa (Multi-center, Open-label, Phase I and Multi-center, Open-label, Phase IIa ) Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
Year2022
CountryAustralia
Company sponsorEyeGene Inc.
Other ID(s)EG-COVID-102

Clinical Result

Cohort1: EG-COVID-003
Administration route intramuscular injection
Dosage EG-COVID-003, 0.5mL (mRNA 100μg)
Age Adult, Older_Adult
Cohort2: EG-COVID-001
Administration route intramuscular injection
Dosage EG-COVID-001, 0.5mL (mRNA 200μg)
Age Adult, Older_Adult
Cohort3: EG-COVID_dose level 1
Administration route intramuscular injection
Dosage EG-COVID, 0.5mL (mRNA 400μg)
Age Adult, Older_Adult
Cohort4: EG-COVID_dose level 2
Administration route intramuscular injection
Dosage EG-COVID, 1mL (mRNA 800μg)
Age Adult, Older_Adult
Cohort5: EG-COVARo
Administration route intramuscular injection
Dosage EG-COVARo, 0.5mL (mRNA 800μg)
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph